backgroundaim
interferon
ribavirin
combin
therapi
chronic
hepat
c
induc
low
respons
rate
human
immunodefici
viru
hiv
infect
patient
assess
impact
intensif
interferon
administr
addit
amantadin
efficaci
safeti
standard
antihepat
c
viru
hcv
treatment
hivinfect
patient
method
multicentr
prospect
openlabel
random
phase
iii
clinic
trial
eighti
coinfect
patient
random
receiv
ribavirin
mgday
combin
group
interferon
miu
thrice
weekli
group
b
miu
daili
plu
amantadin
mgday
treatment
durat
week
accord
hcv
genotyp
result
fortyon
patient
random
group
group
b
intentiontotreat
analysi
show
sustain
virolog
respons
defin
hcvrna
negativ
month
stop
treatment
patient
group
group
b
p
lack
drop
hcvrna
level
week
treatment
show
predict
valu
lack
sustain
respons
conclus
amantadin
addit
interferon
intensif
improv
low
efficaci
combin
interferon
alfa
plu
ribavirin
hivhcv
coinfect
patient
patient
earli
virolog
respons
probabl
sustain
respons
q
preval
hepat
c
viru
hcv
infect
among
antihuman
immunodefici
viru
hiv
seroposit
patient
histori
intraven
drug
use
idu
transfus
greater
extens
use
highli
activ
antiretrovir
therapi
haart
dramat
chang
prognosi
hiv
infect
prolong
improv
life
antihiv
seroposit
hand
mortal
morbid
liver
diseas
increas
significantli
consequ
treatment
chronic
hepat
c
coinfect
patient
becom
mandatori
interferon
combin
ribavirin
gold
standard
treatment
chronic
hepat
c
hivuninfect
patient
induc
rate
sustain
respons
howev
cumul
sustain
virolog
respons
svr
observ
confid
interv
ci
patient
enrol
four
pilot
uncontrol
studi
aim
assess
efficaci
toler
ribavirin
plu
interferon
administ
thrice
weekli
hivhcv
coinfect
patient
urgent
need
new
effect
treatment
schedul
hepat
c
hiv
coinfect
patient
among
patient
treat
interferon
alfa
three
time
weekli
intermitt
increas
hcv
viral
load
observ
treatmentfre
day
daili
administr
interferon
could
maintain
sustain
antivir
effect
hcv
schedul
expect
increas
efficaci
interferon
alfa
amantadin
tricycl
amin
antivir
activ
toga
myxo
arena
flaviand
coronaviru
compar
studi
recent
demonstr
statist
signific
advantag
addit
amantadin
interferon
ribavirin
combin
hivuninfect
patient
chronic
hepat
c
nonrespond
previou
cycl
interferon
monotherapi
thu
addit
amantadin
intensif
interferon
schedul
daili
administr
could
expect
increas
efficaci
standard
combin
treatment
ribavirin
interferon
administ
thrice
weekli
order
test
hypothesi
design
multicentr
random
control
trial
compar
efficaci
safeti
new
treatment
schedul
chronic
hepat
c
includ
ribavirin
amantadin
daili
interferon
alfa
administr
standard
combin
treatment
april
octob
hivhcv
coinfect
patient
consecut
enrol
multicentr
prospect
openlabel
random
phase
iii
clinic
trial
studi
conduct
master
hivhcv
coinfect
studi
group
elig
criteria
includ
age
year
alanin
aminotransferas
alt
level
upper
limit
normal
uln
month
enrol
studi
detect
plasma
hcvrna
qualit
test
polymeras
chain
reaction
pcr
amplicor
w
roch
diagnost
system
hoffmanla
roch
basel
switzerland
proven
hivab
seroposit
elisa
confirm
western
blot
stabl
hiv
diseas
cell
count
persist
last
month
antiretrovir
treatment
art
start
least
month
enrol
demonstr
effect
need
art
exclus
hepatocellular
carcinoma
imag
alphafetoprotein
level
lower
ngml
willing
consum
alcohol
treatment
period
exclus
criteria
reactiv
hepat
b
surfac
antigen
hbsag
neutropenia
fewer
neutrophil
per
ml
anaemia
less
gdl
haemoglobin
women
less
gdl
men
thrombocytopenia
fewer
platelet
per
ml
decompens
liver
diseas
serum
creatinin
level
time
uln
poorli
control
psychiatr
diseas
alcohol
drug
depend
year
prior
enrol
substanti
coexist
medic
condit
except
hiv
coinfect
previou
treatment
ifn
alfa
ribavirin
amantadin
system
antineoplast
immunomodulatori
treatment
preced
month
currentpres
hivrel
opportunist
infect
malign
classifi
aid
defin
event
accord
cdc
aid
surveil
case
definit
concomit
medic
rifampicin
andor
rifabutin
andor
isoniazid
andor
pyrazinamid
andor
gancyclovir
evid
excess
alcohol
consumpt
g
male
g
femal
andor
illeg
substanc
abus
within
last
month
coexist
caus
liver
diseas
addit
contraind
drug
use
studi
addit
exclus
criteria
pregnanc
lactat
refus
practis
effect
contracept
treatment
followup
random
control
clinic
trial
conduct
italian
centr
april
decemb
patient
randomli
assign
ratio
block
size
five
receiv
group
interferon
alpha
ifna
million
unit
miu
subcutan
sc
three
time
per
week
plu
daili
per
po
ribavirin
copegu
w
roch
mg
tablet
group
b
ifna
miu
sc
daili
plu
ribavirin
copegu
w
roch
mg
tablet
amantadin
mantadan
w
bohering
ingelheim
mg
tablet
po
mg
everi
h
ribavirin
given
oral
food
dose
mgday
two
tablet
bid
everi
h
patient
kg
bodi
weight
mgday
two
tablet
morn
three
even
h
patient
kg
bodi
weight
treatment
durat
differ
accord
hcv
genotyp
week
hcv
genotyp
week
hcv
genotyp
hcvrna
neg
week
accord
intern
guidelin
random
central
coordin
centr
stratifi
accord
hcv
genotyp
genotyp
vs
genotyp
perform
revers
hybrid
assay
inno
lipa
hcv
ii
innogenet
ghent
belgium
patient
follow
treatmentfre
period
week
cessat
therapi
institut
review
board
particip
centr
approv
protocol
patient
provid
written
inform
consent
studi
conduct
accord
declar
helsinki
applic
regulatori
requir
ichcpmp
guidelin
good
clinic
practic
clinic
examin
laboratori
test
includ
lactic
acid
bicarbon
haematolog
count
includ
cell
count
perform
monthli
plasma
hivrna
monitor
everi
month
use
commerci
avail
test
quantiplex
rna
assay
chiron
corpor
emeryvil
california
usa
hcvrna
measur
time
week
commerci
avail
secondgener
rtpcr
test
amplicor
monitor
version
roch
diagnost
system
pleasanton
ca
accord
manufactur
instruct
presenc
hcvrna
plasma
determin
week
end
treatment
week
cessat
therapi
use
commerci
avail
secondgener
rtpcr
test
amplicor
hcv
roch
diagnost
system
pleasanton
ca
low
end
detect
limit
iuml
accord
manufactur
instruct
primari
measur
efficaci
endoftreat
respons
eotr
svr
respect
defin
hcvrna
level
iuml
end
treatment
week
treatment
measur
safeti
chang
cell
count
hivrna
level
rate
withdraw
advers
event
ae
dropout
rate
withdraw
art
switch
antiretrovir
difficulttotreat
patient
nonrespond
interferon
monotherapi
tripl
therapi
proven
increas
least
three
time
sustain
viral
respons
rate
obtain
standard
interferon
ribavirin
combin
order
establish
svr
tripl
therapi
arm
least
three
time
higher
sustain
respons
rate
observ
hivcoinfect
patient
treat
interferon
ribavirin
pilot
studi
calcul
least
patient
enrol
confid
probabl
signific
level
use
intent
treat
itt
per
protocol
pp
analys
perform
categor
variabl
compar
use
fisher
exact
test
distribut
continu
variabl
compar
use
ttest
mannwhitney
twosampl
statist
test
wilcoxon
ranksum
test
relationship
patient
baselin
characterist
svr
examin
univari
logist
regress
analysi
assess
independ
factor
multivari
logist
regress
analysi
perform
backward
select
p
valu
report
twosid
p
consid
signific
statist
analysi
perform
use
stata
softwar
version
stata
corpor
colleg
station
tx
usa
eighti
patient
enrol
studi
randomli
assign
group
group
b
baselin
characterist
shown
tabl
differ
found
demograph
clinic
immunovirolog
characterist
two
group
sixti
patient
take
art
month
accord
inclus
criteria
start
antihcv
treatment
rate
hcvrna
clearanc
group
shown
tabl
itt
analysi
show
eotr
group
group
b
end
month
followup
respons
rate
decreas
half
svr
observ
group
group
b
differ
absolut
hcvrna
level
hcvrna
changeov
baselin
two
group
time
statist
signific
tabl
show
distribut
baselin
characterist
patient
without
svr
viroimmunolog
art
characterist
also
analyz
test
reveal
relationship
svr
genotyp
gamma
glutamyl
transferas
ggt
baselin
level
less
time
upper
limit
normal
rang
frequent
patient
svr
p
fisher
exact
test
univari
logist
regress
show
role
predict
factor
svr
odd
ratio
ci
ci
respect
aspart
aminotransferas
ast
neutrophil
baselin
level
respect
lower
higher
patient
obtain
svr
p
mann
whitney
test
perform
multivari
logist
regress
found
genotyp
ggt
baselin
valu
independ
predict
factor
svr
tabl
week
patient
still
activ
treatment
virolog
respons
defin
decreas
baselin
hcvrna
level
detect
serum
hcvrna
fig
virolog
respons
subsequ
svr
drop
advers
event
spontan
stop
treatment
sustain
hcvrna
negativ
show
breakthrough
reduc
dose
ribavirin
patient
relaps
stop
treatment
eighteen
test
hcvrna
neg
week
sustain
respons
rate
group
differ
significantli
observ
subject
detect
hcvrna
week
contrast
patient
virolog
respons
drop
ae
prematur
stop
treatment
show
hcvrna
negativ
two
patient
show
etr
none
show
svr
twentyf
patient
stop
treatment
prematur
patient
withdrew
due
ae
independ
stop
therapi
distribut
ae
similar
two
treatment
group
pp
analysi
show
svr
group
group
b
signific
differ
two
treatment
arm
treatment
schedul
modifi
show
increas
hivrna
level
time
treatment
need
switch
art
due
loss
efficaci
statist
signific
differ
found
hivrna
level
two
treatment
group
time
eleven
patient
undergo
treatment
didanosin
stavudin
six
lactic
acidosi
observ
patient
main
find
studi
poor
rate
svr
combin
standard
interferon
ribavirin
observ
treatment
arm
without
amantadin
interferon
dose
intensif
cumul
treat
patient
complet
treatment
cours
clear
hcvrna
respons
rate
significantli
lower
svr
rate
report
trial
perform
hiv
seroneg
high
withdraw
rate
larg
number
subject
requir
adjust
treatment
schedul
low
respons
rate
observ
complet
treatment
schedul
suggest
toler
efficaci
interferon
alfa
ribavirin
combin
reduc
hivcoinfect
subject
proport
patient
need
interferon
dose
reduct
significantli
higher
group
b
find
statist
signific
differ
rate
eotr
svr
two
treatment
arm
therefor
combin
interferon
alfa
schedul
intensif
amantadin
addit
neither
increas
efficaci
improv
toler
combin
therapi
coinfect
hivhcv
patient
clinic
trial
pegyl
interferon
formul
combin
ribavirin
ongo
hivhcvcoinfect
patient
preliminari
result
suggest
increas
interferon
level
induc
pegyl
interferon
could
improv
respons
rate
hivhcvcoinfect
patient
amantadin
addit
improv
efficaci
toler
interferon
alpha
ribavirin
chronic
hcv
infect
howev
given
low
power
studi
addit
studi
need
drug
discard
therapeut
armamentarium
hivhcv
coinfect
univari
logist
regress
analysi
factor
predict
svr
confirm
age
sex
degre
fibrosi
baselin
hcvrna
level
report
hiv
seroneg
patient
probabl
due
small
size
sampl
studi
result
studi
show
half
patient
svr
past
reach
cell
count
less
low
nadir
count
year
preced
treatment
preclud
achiev
svr
find
togeth
absenc
associ
fibrosi
score
count
svr
suggest
progress
hcv
hiv
infect
decreas
respons
rate
interferon
ribavirin
combin
patient
without
sever
immun
deplet
therefor
hypothes
patient
without
high
probabl
respons
earli
stage
liver
fibrosi
watch
wait
strategi
would
reduc
potenti
efficaci
antihcv
treatment
hypothesi
need
confirm
larger
studi
metaanalysi
multipl
pilot
studi
hcv
genotyp
earli
hcvrna
clearanc
ggt
level
signific
predictor
svr
multivari
analysi
associ
hcv
genotyp
higher
rate
svr
well
known
confirm
antihiv
seroposit
pilot
studi
two
respond
infect
hcv
genotyp
svr
rate
patient
infect
genotyp
take
account
side
effect
treatment
data
suggest
low
cost
effect
treatment
standard
interferon
ribavirin
hiv
seroposit
infect
hcv
genotyp
associ
earlier
hcv
clearanc
svr
suggest
suppress
hcv
replic
earli
phase
treatment
necessari
suffici
induc
svr
high
serum
ggt
chronic
hepat
c
patient
frequent
associ
sever
hepat
fibrosi
cirrhosi
steatosi
may
part
account
poor
respons
interferon
therapi
ggt
alter
hiv
seroposit
patient
frequent
possibl
correl
one
follow
factor
hepat
steatosi
andor
lipid
dismetabol
drugrel
hepat
toxic
especi
patient
undergo
art
excess
alcohol
consumpt
hcvrelat
hepat
damag
especi
genotyp
immunomedi
biliari
duct
damag
although
includ
patient
deni
alcohol
abus
rule
high
ggt
level
due
undeclar
excess
alcohol
consumpt
bodi
mass
index
significantli
associ
treatment
respons
one
svr
show
high
ggt
baselin
patient
ggt
normal
third
month
hcvrna
negativ
evalu
art
toxic
care
assess
alcohol
intak
correct
alcohol
abus
diagnosi
treatment
alter
lipid
metabol
factor
evalu
start
treatment
chronic
hepat
c
patient
coinfect
hiv
studi
lack
drop
hcvrna
level
week
treatment
show
neg
predict
valu
svr
although
data
interpret
caution
given
high
proport
do
result
reinforcessupport
observ
nearli
absolut
neg
predict
valu
lack
virolog
respons
hcv
noninfect
patient
treat
pegyl
interferon
enter
era
hcv
treatment
go
pursu
aggress
hivhcvcoinfect
person
emphasi
must
place
identifi
earli
stage
subject
benefit
expens
poorli
toler
therapi
result
confirm
larger
studi
antihcv
treatment
could
stop
week
without
decreas
expect
rate
svr
hivinfect
patient
show
least
drop
hcvrna
level
conclus
intensif
interferon
alpha
schedul
amantadin
addit
appear
improv
limit
efficaci
standard
combin
therapi
includ
interferon
thrice
weekli
plu
ribavirin
treatment
chronic
hepat
c
hivcoinfect
patient
best
candid
antihcv
treatment
patient
infect
hcv
genotyp
normal
ggt
level
lack
drop
hcvrna
level
week
treatment
seem
highli
predict
poor
efficaci
antihcv
treatment
paolo
ospedal
umberto
veneziamestr
apoggio
v
mondino
division
di
malatti
infett
ospedal
di
verbania
tinelli
mc
cerri
division
di
malatti
infett
ospedal
di
lodi
